首页> 美国卫生研究院文献>mAbs >IBCs 21st Annual Antibody Engineering and 8th Annual Antibody Therapeutics International Conferences and 2010 Annual Meeting of The Antibody Society
【2h】

IBCs 21st Annual Antibody Engineering and 8th Annual Antibody Therapeutics International Conferences and 2010 Annual Meeting of The Antibody Society

机译:IBC第21届年度抗体工程和第8届年度抗体治疗国际会议和抗体学会2010年年会

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The 21st Annual Antibody Engineering and 8th Annual Antibody Therapeutics international conferences, and the 2010 Annual Meeting of The Antibody Society, organized by IBC Life Sciences with contributions from The Antibody Society and two Scientific Advisory Boards, was held December 5–9, 2010 in San Diego, CA. The conferences featured over 100 presentations and 100 posters, and included a pre-conference workshop on deep-sequencing of antibody genes. The total number of delegates exceeded 800, which set a new attendance record for the conference.The conferences were organized with a focus on antibody engineering only on the first day and a joint engineering/therapeutics session on the last day. Delegates could select from presentations that occurred in two simultaneous sessions on days 2 and 3. Day 1 included presentations on neutralizing antibodies and the identification of vaccine targets, as well as a historical overview of 20 years of phage display utilization. Topics presented in the Antibody Engineering sessions on day 2 and 3 included antibody biosynthesis, structure and stability; antibodies in a complex environment; antibody half-life; and targeted nanoparticle therapeutics. In the Antibody Therapeutics sessions on days 2 and 3, preclinical and early stage development and clinical updates of antibody therapeutics, including TRX518, SYM004, MM111, PRO140, CVX-241, ASG-5ME, U3-1287 (AMG888), R1507 and trastuzumab emtansine, were discussed and perspectives were provided on the development of biosimilar and biobetter antibodies, including coverage of regulatory and intellectual property issues. The joint engineering/therapeutics session on the last day focused on bispecific and next-generation antibodies. Summaries of most of the presentations are included here, but, due to the large number of speakers, it was not possible to include summaries for every presentation.Delegates enjoyed the splendid views of the San Diego Bay and proximity to the Gaslamp Quarter provided by the venue. The 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics conferences, and the 2011 Annual Meeting of The Antibody Society, are planned for December 5–8, 2011 at the same location in San Diego, and will include two two-day short courses on Introduction to Antibody Engineering and Protein Characterization for Biotechnology Product Development.
机译:由IBC Life Sciences组织,由抗体协会贡献的第21届年度抗体工程和第8届年度抗体治疗国际会议,以及2010年抗体学会年会和两个科学顾问委员会,于2010年12月5日至9日在加利福尼亚州圣地亚哥举行。这些会议以100多个演讲和100个海报为特色,并包括一个关于抗体基因深度测序的会前研讨会。与会代表总数超过800人,为会议创造了新的出席记录。这些会议仅在第一天就组织了抗体工程学会议,而在最后一天则进行了联合工程学/治疗学会议。代表可以从在第2天和第3天同时进行的两次会议中进行的演讲中进行选择,第一天包括有关中和抗体和疫苗靶标鉴定的演讲,以及20年噬菌体展示利用的历史回顾。第2天和第3天的抗体工程会议上介绍的主题包括抗体的生物合成,结构和稳定性。复杂环境中的抗体;抗体半衰期;和有针对性的纳米粒子疗法。在第2天和第3天的抗体治疗学会议上,抗体治疗剂的临床前和早期开发以及临床更新,包括TRX518,SYM004,MM111,PRO140,CVX-241,ASG-5ME,U3-1287(AMG888),R1507和曲妥珠单抗讨论了鞣花碱,并提供了有关生物仿制药和生物仿制药抗体发展的观点,包括监管和知识产权问题的涵盖范围。最后一天的联合工程/治疗学会议侧重于双特异性抗体和下一代抗体。大多数演讲的摘要都包含在此处,但是由于演讲者众多,因此无法为每个演讲都提供摘要。代表们欣赏了圣地亚哥湾的壮丽景色以及加蓬在加斯兰普区附近的景致。场地。计划于2011年12月5日至8日在圣地亚哥的同一地点举行第22届年度抗体工程和第9届年度抗体治疗学会议以及2011年抗体学会年会。两期为期两天的短期课程,内容涉及用于生物技术产品开发的抗体工程和蛋白质表征简介。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号